BFL-1 BH3 mimetic (Janssen Research & Development)

N/A

Report date: 2025/06/11 10:38:28
NME

Base Information

Drug NameBFL-1 BH3 mimetic (Janssen Research & Development)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionBcl-2-related protein A1 inhibitorsApoptosis stimulants
TargetsBcl-2-related protein A1
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJanssen Research & Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A